Jim Simons Genmab A/S Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Genmab A/S stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,786,428 shares of GMAB stock, worth $35.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

1,786,428

Previous 1,462,459 22.15%

Holding current value

$35.8 Million

Previous $36.8 Million 18.51%

% of portfolio

0.07%

Previous 0.06%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$23.84 - $28.48 $7.72 Million - $9.23 Million	323,969 Added 22.15%	1,786,428 $43.6 Million
Q2 2024 Aug 09, 2024	BUY	$25.13 - $30.27 $2.61 Million - $3.14 Million	103,859 Added 7.64%	1,462,459 $36.8 Million
Q1 2024 May 13, 2024	SELL	$26.43 - $32.77 $3.6 Million - $4.46 Million	-136,200 Reduced 9.11%	1,358,600 $40.6 Million
Q4 2023 Feb 13, 2024	BUY	$27.94 - $35.44 $8.96 Million - $11.4 Million	320,800 Added 27.33%	1,494,800 $47.6 Million
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $11.8 Million - $14.1 Million	334,900 Added 39.91%	1,174,000 $41.4 Million
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $7.87 Million - $9.04 Million	-210,500 Reduced 20.06%	839,100 $31.9 Million
Q1 2023 May 12, 2023	SELL	$34.88 - $43.22 $4.92 Million - $6.1 Million	-141,100 Reduced 11.85%	1,049,600 $39.6 Million
Q4 2022 Feb 13, 2023	BUY	$33.8 - $47.06 $9.27 Million - $12.9 Million	274,300 Added 29.93%	1,190,700 $50.5 Million
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $2.01 Million - $23.8 Million	-63,800 Reduced 6.51%	916,400 $29.4 Million
Q2 2022 Aug 12, 2022	SELL	$26.83 - $38.57 $2.91 Million - $4.18 Million	-108,300 Reduced 9.95%	980,200 $31.8 Million
Q1 2022 May 13, 2022	BUY	$30.95 - $39.68 $436,395 - $559,488	14,100 Added 1.31%	1,088,500 $39.4 Million
Q4 2021 Feb 11, 2022	BUY	$35.87 - $47.12 $6.3 Million - $8.27 Million	175,600 Added 19.54%	1,074,400 $42.5 Million
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $577,545 - $677,208	13,900 Added 1.57%	898,800 $39.3 Million
Q2 2021 Aug 13, 2021	SELL	$32.88 - $44.57 $3.53 Million - $4.79 Million	-107,400 Reduced 10.82%	884,900 $36.1 Million
Q1 2021 May 13, 2021	SELL	$30.92 - $44.4 $9.86 Million - $14.2 Million	-318,900 Reduced 24.32%	992,300 $32.6 Million
Q4 2020 Feb 10, 2021	SELL	$33.66 - $40.76 $11.8 Million - $14.3 Million	-352,000 Reduced 21.16%	1,311,200 $53.3 Million
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $18.5 Million - $21.7 Million	560,103 Added 50.78%	1,663,200 $60.9 Million
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $19.1 Million - $32.4 Million	954,697 Added 643.33%	1,103,097 $37.4 Million
Q1 2020 May 14, 2020	BUY	$17.15 - $25.22 $2.55 Million - $3.74 Million	148,400 New	148,400 $3.15 Million

Others Institutions Holding GMAB

# of Institutions

238

Shares Held

52.6M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.2B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account